Fidson Healthcare to Raise $50 Million for Global Expansion and Manufacturing Boost

Fidson Healthcare Plc, one of Nigeria’s leading pharmaceutical giants, has unveiled a bold investment plan worth $50 million aimed at strengthening its manufacturing capabilities and expanding its footprint beyond Nigeria. This strategic initiative, set to unfold over the next three years, will be funded through a combination of equity and debt financing.

Dr. Fidelis Ayebae, the outgoing Managing Director and Chief Executive Officer of Fidson Healthcare, disclosed the plan during an exclusive interview with Nairametrics. His announcement comes at a time of renewed focus on local drug manufacturing and self-sufficiency within Nigeria’s health sector. Dr. Ayebae’s vision is clear: Fidson wants to not only dominate Nigeria’s pharmaceutical market but also emerge as a significant player on the global stage.

“Fidson is investing $50 million in the next three years,” Ayebae said. “I am now retiring to ensure that we raise the necessary funds through equity and debt to fund that and make it happen, because we have faith in the economy.”

At the heart of this investment is a two-pronged objective: ramping up domestic production and entering new international markets. The expansion will improve operational efficiency, boost supply chain resilience, and enhance Fidson’s competitiveness in a sector increasingly shaped by global demand and technological innovation.

This development aligns with ongoing efforts by the Nigerian government to stimulate local pharmaceutical production and reduce the country’s dependence on imported medicines. According to Ayebae, Fidson is actively working to meet the government’s call for local manufacturers to supply at least 70 percent of Nigeria’s medicine needs.

Currently, local manufacturers are estimated to supply about 50 to 60 percent of total national pharmaceutical demand, an encouraging jump from just 30 to 40 percent a few years ago. This shift is being driven by investment across the sector, with at least 10 pharmaceutical firms reportedly expanding operations in response to the government’s push.

Dr. Ayebae was full of praise for the current administration under President Bola Tinubu, especially for its proactive policies that are enabling local industries to thrive. In particular, he cited a presidential directive that eliminates import duties on raw materials and packaging components for two years. This policy, he noted, has already had a meaningful impact on the bottom line for manufacturers and has incentivized expansion projects like Fidson’s.

“The removal of import duties on raw and packaging materials has been very helpful. It encourages manufacturers like us to increase local production and build capacity,” Ayebae said.

This level of government backing is seen as a turning point in Nigeria’s decades-long quest to develop a self-reliant pharmaceutical ecosystem. With Nigeria’s population exceeding 220 million and demand for affordable, high-quality medication continuing to grow, Fidson’s investment arrives at a pivotal moment.

The investment announcement was made during the Fidson Distributors Awards 2025, an event organized to celebrate top-performing pharmaceutical distributors across the country. The ceremony underscored Fidson’s commitment to deepening its distribution network while also recognizing the critical role that partners play in the company’s growth journey.

Notable award recipients included:

Nwachukwu John of Nwachukwu Pharmaceuticals, who won Best Distributor National and Best Distributor for the East Division.

Oliver Anyadiegwu of Zimaco Pharm Ltd, who was awarded Best Distributor for the Lagos Division.

Pharm Abiola Adekunle of Kunle Ara Pharm, named Best Distributor for the West Division.

Alhaji Sayyidi Atana of Latnas Pharmaceuticals, who clinched the Best Distributor award for the North Division.

The event was more than a celebration, it served as a rallying call for regional growth and international scaling, emphasizing the importance of strong distribution channels in achieving Fidson’s expansion goals.

Fidson’s ambitious plans are underpinned by a strong financial performance in the first quarter of 2025. The company posted a pre-tax profit of ₦4.8 billion, marking a remarkable 213.49 percent increase compared to the ₦1.5 billion reported in Q1 2024.

This impressive profit growth was driven by a significant surge in revenue, which soared to ₦35 billion, up 85.42 percent from ₦18.8 billion in the same period last year.

A closer look at Fidson’s revenue streams reveals that its ethical product line accounted for the lion’s share, generating ₦22.9 billion. This was followed by over-the-counter (OTC) products, which brought in ₦10.04 billion.

However, the rapid scale-up has also come with rising operational costs. The company’s cost of sales jumped to ₦22.4 billion, representing a 100.23 percent increase from ₦11.2 billion in Q1 2024. Despite this, Fidson remains financially solid and well-positioned to sustain its growth plans.

With this new $50 million investment strategy, Fidson Healthcare is positioning itself as a leader in Nigeria’s journey toward pharmaceutical self-sufficiency and global relevance. The company’s focus on manufacturing excellence, local sourcing, and international market entry represents a strategic alignment with both national priorities and global healthcare trends.

As Dr. Ayebae prepares to hand over the reins, he leaves behind a legacy of transformation and a clear roadmap for Fidson’s next chapter. From policy-driven growth to impressive quarterly results, the company’s story serves as a model for how public-private synergy can reshape industries.

If successfully executed, Fidson’s expansion could be a game-changer not just for the company, but for Nigeria’s healthcare ecosystem as a whole.